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Objectives The present analysis reports on the pre-specified subgroup of ST-elevation myocardial infarction (STEMI) pa-
tients, in whom anticoagulant therapy has been of particular interest.
Background In ATLAS ACS-2–TIMI-51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in
Subjects with Acute Coronary Syndrome–Thrombolysis In Myocardial Infarction-51), rivaroxaban reduced cardio-
vascular events across the spectrum of acute coronary syndrome (ACS).
Methods Seven thousand eight hundred seventeen patients in ATLAS ACS-2-TIMI 51 presented with a STEMI. After being
stabilized (1 to 7 days), they underwent randomization to twice daily rivaroxaban 2.5 mg, rivaroxaban 5 mg, or
placebo. Data are presented as 2-year Kaplan-Meier rates, and for intention-to-treat (ITT) and modified ITT (mITT)
analyses.
Results Among STEMI patients, rivaroxaban reduced the primary efficacy endpoint of cardiovascular death, myocardial
infarction, or stroke, compared with placebo (ITT: 8.4% vs. 10.6%, hazards ratio [HR]: 0.81, 95% confidence in-
terval [CI]: 0.67 to 0.97, p  0.019; mITT: 8.3% vs. 9.7%, HR: 0.85, 95% CI: 0.70 to 1.03, p  0.09). This reduc-
tion emerged by 30 days (ITT and mITT: 1.7% vs. 2.3%, p  0.042) and was evident in analyses that included
events while patients received background dual antiplatelet therapies (ITT: 7.9% vs. 11.9%, p  0.010; mITT:
7.7% vs. 10.1%, p  0.061). In terms of the individual doses, rivaroxaban 2.5 mg reduced cardiovascular death
(ITT: 2.5% vs. 4.2%, p  0.006; mITT: 2.2% vs. 3.9%, p  0.006), which was not seen with 5 mg of rivaroxaban.
Rivaroxaban versus placebo increased non-coronary artery bypass grafting Thrombolysis In Myocardial Infarction
major bleeding (2.2% vs. 0.6%, p  0.001) and intracranial hemorrhage (0.6% vs. 0.1%, p  0.015) without a
significant increase in fatal bleeding (0.2% vs. 0.1%, p  0.51).
Conclusions In patients with a recent STEMI, rivaroxaban reduced cardiovascular events. This benefit emerged early and per-
sisted during continued treatment with background antiplatelet therapies. Rivaroxaban compared with placebo
increased the rate of major bleeding, but there was no significant increase in fatal bleeding. (An Efficacy and
Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome; NCT00809965) (J Am Coll Cardiol
2013;61:1853–9) © 2013 by the American College of Cardiology Foundation
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Rivaroxaban in STEMI May 7, 2013:1853–9Morbidity and mortality rates
following ST-segment elevation
myocardial infarction (STEMI)
have declined over time due in
part to the delivery of timely
reperfusion and in-hospital treat-
ment with anticoagulant and an-
tiplatelet therapies (1,2). None-
theless, the cumulative risk of
death and ischemic events per-
sists during the initial treat-
ment period and after the acute
STEMI event (3). Thus, ways to
prevent future complications in
this at-risk patient population
continue to be explored.
ATLAS ACS-2–TIMI-51
(Anti-Xa Therapy to Lower
Cardiovascular Events in Addi-
tion to Standard Therapy in
Subjects with Acute Coronary
Syndrome–Thrombolysis In Myocardial Infarction-51) is the
largest study to date to test a novel Xa inhibitor, rivaroxaban, in
patients with an acute coronary syndrome (ACS). In the trial, as
a whole, rivaroxaban reduced recurrent cardiovascular events
across the spectrum of ACS (4,5). The present analysis
focuses on the results of rivaroxaban versus placebo in the
pre-specified subgroup of patients following a STEMI, in
whom long-term anticoagulant therapy has been of partic-
ular interest. In addition, this analysis addresses several
other key aspects of the trial: 1) the results of rivaroxaban
versus placebo early after initiation of therapy, during a time
when the post-STEMI event rates are at their highest; 2)
the effect of rivaroxaban among patients who continued
their background antiplatelet therapies, thus providing a
particularly rigorous test of the additive role of this novel
anticoagulant; and 3) further material on data completeness.
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Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass grafting
CI  confidence interval
HR  hazard ratio
ITT  intention-to-treat
MI  myocardial infarction
mITT  modified
intention-to-treat
NSTEMI  non–ST-
elevation MI
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial InfarctionManuscript received November 21, 2012; revised manuscript received January 7,
2013, accepted January 15, 2013.Methods
Study population. ATLAS ACS-2-TIMI-51 was a ran-
domized, double-blind, placebo-controlled, event-driven trial that
included 15,526 patients (18 years of age without an upper
age limit) who presented with symptoms suggestive of
ACS and a diagnosis of STEMI, non–ST-elevation MI
(NSTEMI), or unstable angina. Patients were enrolled
within 1 to 7 days after hospital admission. They needed to
be stabilized before enrollment, with the initial manage-
ment strategies completed. Patients were randomized in a
1:1:1 fashion to twice daily administration of either rivar-
oxaban 2.5 mg, rivaroxaban 5 mg, or placebo. They received
standard care, including low-dose aspirin therapy and a
thienopyridine (either clopidogrel or ticlopidine per the
national or local guidelines). The key eligibility criteria and
definitions of the endpoints have been published (4).
Statistical analysis. Rates of the endpoints were expressed
as Kaplan-Meier event rates through 24 months. Treatment
groups were evaluated using hazard ratios (HRs) and
2-sided 95% confidence intervals (CIs) using Cox propor-
tional hazard models. Testing occurred between doses of
rivaroxaban and placebo, based on the log-rank test, strat-
ified by the intention to use a thienopyridine. The term
rivaroxaban refers to the combined doses unless the indi-
vidual doses are indicated. As pre-specified, this analysis
focused on a subgroup of patients based on the index event
(i.e., STEMI). Additionally, analyses were conducted that
included events that occurred while patients were continu-
ing on dual antiplatelet therapy. Exploratory analyses were
conducted through 30 days. Data for the efficacy endpoints
are presented for the intention-to-treat (ITT) analysis to
provide complete accounting of events and for the modified
intention-to-treat (mITT) analysis. The ITT analysis con-
sists of all randomized patients and all first endpoint events
through the global treatment end date. The mITT analysis
consists of all randomized patients and the first endpoint
events that occurred no later than: 1) the global treatment
end date; 2) 30 days following early permanent discontin-
uation of the study drug; or 3) 30 days following random-
ization for patients who did not receive study drug. Thus,
the mITT events are a subset of the ITT events. Before
unblinding, 90 patients within the STEMI subgroup were
excluded from the efficacy analyses due to trial misconduct
at 3 sites. Data for the safety endpoints corresponds to the
safety analysis set (4).
Results
In ATLAS ACS-2–TIMI-51, a total of 7,817 patients
presented with a STEMI. The baseline characteristics of the
STEMI patients were well matched across the treatment
groups (Table 1). Background therapy included aspirin and
a thienopyridine in 98.8% and 96.8% of the patients,
respectively. Among the STEMI population, the median
time from index STEMI to randomization was 4.7 days
(interquartile range: 3.3 to 6.0 days).
rance;
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May 7, 2013:1853–9 Rivaroxaban in STEMIThe rates of withdrawal of consent were 8.5% for rivar-
oxaban 2.5 mg twice daily, 7.9% for rivaroxaban 5 mg twice
daily, and 7.2% for placebo (p  0.23). Additionally, the
observed follow-up years were 3,132 (94.3% of the complete
follow-up time) for rivaroxaban 2.5 mg twice daily, 3,114
(94.5%) for rivaroxaban 5 mg twice daily, and 3,155 (94.7%)
Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristics
Rivaroxaba
Twice
(n  2
Age, yrs 61.5
65 881
75 186
Male 2,059 (7
Weight, kg 78.5
Cr Cl, ml/min 89.1
Medical history
MI 411 (1
Hypertension 1,505 (5
Diabetes 761 (2
Hypercholesterolemia 1,061 (4
Race
White 1,899 (7
Black 11 (0
Asian 563 (2
Other 128 (4
Index diagnosis
Index ACS to randomization, days 4.7
Anterior MI 1,155 (4
Left ventricular ejection fraction, %* 50.7
PCI 1,868 (7
PTCA 107 (4
Bare-metal stent 1,205 (4
Drug-eluting stent 556 (2
CABG for index 7 (0
Lytic therapy 674 (2
Region
North America 121 (4
South America 282 (1
Western Europe 399 (1
Eastern Europe 1,001 (3
Asia Pacific 558 (2
Other 240 (9
Medications
Duration of study drug, days 403 (2
Aspirin 2,566 (9
Duration of aspirin, days 478 (2
Thienopyridine 2,507 (9
Duration of thienopyridine,† days 385 (2
Beta-blocker 1,736 (6
ACE-I or ARB 976 (3
Statin 2,219 (8
CCB 274 (1
Values are mean SD, n (%), or median (interquartile range). *Availab
on race were patient-reported. Comparisons resulted in p  0.05 exc
ACE-I angiotensin-converting enzyme inhibitor; ACS acute coron
bypass grafting; CCB calcium channel blocker; Cr Cl creatinine clea
PTCA  percutaneous transluminal coronary angioplasty.for placebo (p  0.82) (Online Fig. 1). The lost tofollow-up rates were 0.3% for rivaroxaban 2.5 mg twice daily
and 0.4% for rivaroxaban 5 mg twice daily and placebo (p
0.88).
Efficacy endpoints. Among patients with a STEMI, rivar-
oxaban reduced the primary efficacy endpoint of cardiovas-
cular death, myocardial infarction, or stroke (ischemic,
mg Rivaroxaban 5 mg
Twice Daily
(n  2,584)
Placebo
(n  2,632)
61.3 8.6 60.8 8.9
875  33.9 816 31.0
178 6.9 190 7.2
2,042 (79.0) 2,056 (78.1)
78.5 15.7 78.0 15.6
89.1 28.4 89.6 28.4
449 (17.4) 441 (16.8)
1,507 (58.3) 1,560 (59.3)
7,37 (28.5) 794 (30.2)
1,045 (40.6) 1,053 (40.3)
1,893 (73.3) 1,935 (73.6)
15 (0.6) 13 (0.5)
559 (21.6) 562 (21.4)
117 (4.5) 120 (4.6)
4.6 1.7 4.6 1.7
1,133 (43.9%) 1,207 (45.9%)
50.8 10.6 50.3 10.6
1,841 (71.2) 1,874 (71.2)
109 (4.2) 122 (4.6)
1,144 (44.3) 1,158 (44.0)
588 (22.8) 594 (22.6)
3 (0.1) 8 (0.3)
634 (24.5) 695 (26.4)
124 (4.8) 129 (4.9)
287 (11.1) 280 (10.6)
420 (16.3) 407 (15.5)
995 (38.5) 1,019 (38.7)
554 (21.4) 556 (21.1)
204 (7.9) 241 (9.2)
7) 382 (200–580) 394 (221–581)
2,556 (98.9) 2,601 (98.8)
8) 470 (295–639) 480 (304–642)
2,513 (97.3) 2,550 (96.9)
8) 379 (253–542) 386 (256–547)
1,756 (68.0) 1,766 (67.1)
959 (37.1) 1,004 (38.1)
2,231 (86.3) 2,241 (85.1)
251 (9.7) 260 (9.9)
894 subjects. †In patients with intent for thienopyridine therapy. Data
age.
rome; ARB angiotensin II receptor blocker; CABG coronary artery
MImyocardial infarction; PCI percutaneous coronary intervention;n 2.5
Daily
,601)
8.8
33.9
7.2
9.2)
15.9
28.8
5.8)
7.9)
9.3)
1.0)
3.0)
.4)
1.6)
.9)
1.7
4.4%)
10.6
1.8)
.1)
6.3)
1.4)
.3)
5.9)
.7)
0.8)
5.3)
8.5)
1.5)
.2)
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8.7)
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Rivaroxaban in STEMI May 7, 2013:1853–9(ITT: 8.4% vs. 10.6%, HR: 0.81, 95% CI: 0.67 to 0.97, p 
0.019; mITT: 8.3% vs. 9.7%, HR: 0.85, 95% CI: 0.70 to
1.03, p  0.09) (Fig. 1), and there was no significant
heterogeneity based on region (pinteraction  0.52). This
eduction in the primary endpoint began to emerge within
he first 30 days (ITT and mITT: 1.7% vs. 2.3%, HR: 0.71,
5% CI: 0.51 to 0.99, p  0.042) (Fig. 2). During this early
ime frame, follow-up data were available for more than
9% of the participants in all 3 treatment groups. Because
ome patients discontinued their antiplatelet agents during
Figure 1 Incidence of the Primary Efficacy Endpoint
The primary efficacy endpoint consists of cardiovascular death, myocardial
infarction (MI), or stroke. Data are presented for the rivaroxaban doses com-
bined compared with placebo. CI  confidence interval; HR  hazard ratio;
ITT  intention-to-treat; mITT  modified ITT.
Figure 2 Incidence of the Primary Efficacy Endpoint
Through 30 Days
The primary efficacy endpoint consists of cardiovascular death, MI, or stroke.
Data are presented for the rivaroxaban doses combined compared with pla-
cebo. Abbreviations as in Figure 1.he study, sensitivity analyses were conducted for events that
ccurred while on treatment with aspirin and a thienopyri-
ine, which yielded consistent results (ITT: 7.9% vs. 11.9%,
R; 0.78, 95% CI: 0.64 to 0.94, p 0.010; mITT: 7.7% vs.
10.1%, HR; 0.82, 95% CI: 0.67 to 1.01, p 0.061) (Fig. 3).
Assessing the components of the primary efficacy end-
oint, rivaroxaban versus placebo yielded ITT and mITT
Rs of 0.76 (95% CI: 0.57 to 1.02) and 0.76 (95% CI: 0.56
o 1.03) for cardiovascular death (which included
emorrhage-related deaths) and 0.78 (95% CI: 0.62 to 0.98)
nd 0.86 (95% CI: 0.67 to 1.09) for MI, respectively. For
troke, the ITT and mITT HRs were 1.42 (95% CI: 0.81 to
.46) and 1.40 (95% CI: 0.79 to 2.48), respectively.
Examining the 2 active treatment doses, rivaroxaban 2.5
nd 5 mg compared with placebo exhibited similar reduc-
ions in the primary efficacy endpoint, without significant
ifferences comparing the 2.5- and 5-mg doses (ITT: 8.7%
s. 8.2%, HR: 0.99, 95% CI: 0.80 to 1.24, p  0.96; mITT:
.8% vs. 7.9%, HR: 0.99, 95% CI: 0.79 to 1.25, p  0.95)
Table 2). Rivaroxaban 2.5 mg reduced cardiovascular death
ITT HR: 0.60, 95% CI: 0.42 to 0.87, p  0.006; mITT
R: 0.58, 95% CI: 0.39 to 0.86, p  0.006) and all-cause
eath (ITT HR: 0.63, 95% CI: 0.45 to 0.89, p  0.008;
mITT HR: 0.60, 95% CI: 0.41 to 0.87, p 0.007) (Fig. 4);
this survival benefit was not seen with 5 mg. This observa-
tion for the 2.5-mg dose was consistent during treatment
with dual antiplatelet therapy (Online Fig. 2) and regardless
of MI location and treatment strategy (Online Fig. 3).
Table 2 provides data for the other efficacy endpoints.
Safety endpoints. Rivaroxaban, compared with placebo,
increased the rates of non-coronary artery bypass grafting
Figure 3
Incidence of the Primary Efficacy Endpoint
for Events That Occurred While Patients
Were on Aspirin and a Thienopyridine
The primary efficacy endpoint consists of cardiovascular death, MI, or stroke.
Data are presented for the rivaroxaban doses combined compared with pla-
cebo. Abbreviations as in Figure 1.(CABG) Thrombolysis In Myocardial Infarction (TIMI)
 mo
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May 7, 2013:1853–9 Rivaroxaban in STEMImajor bleeding (2.2% vs. 0.6%, HR: 4.52, 95% CI: 2.27 to
9.01, p  0.001) (Table 3, Figs. 5 and 6) without evidence
of heterogeneity based on age (Online Table 1). There was
also an increase in intracranial hemorrhage (0.6% vs. 0.1%,
HR: 8.14, 95% CI: 1.08 to 61.37, p  0.015) without a
statistically significant increase in fatal bleeding (0.2% vs.
0.1%, HR: 1.54, 95% CI: 0.42 to 5.70, p  0.51).
Comparing the 2 active treatment arms, rivaroxaban 2.5
mg versus 5 mg resulted in fewer non-CABG TIMI major
or minor bleeding events (2.5% vs. 4.5%, HR: 0.64, 95% CI:
0.45 to 0.93, p  0.02). Additionally, there were fewer
TIMI medical attention bleeds with 2.5 mg versus 5 mg
(12.6% vs. 15.7%, HR: 0.76, 95% CI: 0.64 to 0.89, p 
0.001). Fewer fatal bleeding events occurred with 2.5 mg
versus 5 mg of rivaroxaban (1 event vs. 8 events, p 0.018).
Discussion
Among the patients who presented with a STEMI in
ATLAS ACS-2–TIMI-51, rivaroxaban reduced the pri-
mary efficacy endpoint of cardiovascular death, MI, or
stroke, compared with placebo. In this study, patients were
treated for their initial STEMI event and enrolled within 1
week of their presentation. Evaluating the early effects of
rivaroxaban versus placebo, the reductions in cardiovascular
endpoints emerged shortly after the study initiation. These
findings provide additional insight into factor Xa inhibition
in patients following a STEMI and help support the overall
results of the trial.
The majority of STEMI patients were treated with
aspirin and a thienopyridine (predominantly clopidogrel) at
baseline. When focusing the analyses on STEMI patients
Efficacy EndpointsTable 2 Efficacy Endpoints
Efficacy Endpoints
Rivaroxaban
2.5 mg
(n  2,573)
5 mg
(n  2,555)
Combine
(n  5,12
CV death, myocardial infarction,
or stroke (primary endpoint)
ITT 155 (8.7%) 154 (8.2%) 309 (8.4%
mITT 145 (8.8%) 143 (7.9%) 288 (8.3%
Death from CV causes
ITT 46 (2.5%) 69 (4.0%) 115 (3.3%
miTT 39 (2.2%) 61 (3.4%) 100 (2.8%
Myocardial infarction
ITT 98 (5.7%) 83 (4.0%) 181 (4.8%
mITT 95 (6.1%) 79 (4.2%) 174 (5.1%
Stroke
ITT 24 (1.5%) 24 (1.4%) 48 (1.5%
mITT 22 (1.6%) 22 (1.4%) 44 (1.5%
All-cause death
ITT 54 (3.0%) 83 (5.3%) 137 (4.2%
mITT 44 (2.5%) 65 (3.9%) 109 (3.2%
Values are n (%). Event rates are reported as Kaplan-Meier estimates through 24 months. My
hemorrhagic, and stroke of uncertain cause.
CI  confidence interval; CV  cardiovascular; HR  hazard ratio; ITT  intention-to-treat; mITTcontinuing their antiplatelet therapies, the reductions incardiovascular events with rivaroxaban were maintained. In
the present study, patients were not treated with prasugrel
or ticagrelor, and rivaroxaban in addition to these agents has
not been tested thoroughly. Nonetheless, the cardiovascular
benefits associated with the regimen of rivaroxaban 2.5 mg
twice daily, aspirin, and clopidogrel versus aspirin and
clopidogrel support the results for aspirin and newer aden-
osine diphosphate receptor blockers versus aspirin and
clopidogrel (6,7). In aggregate, these studies underscore the
efficacy of greater degrees of antithrombotic therapy beyond
aspirin and standard dose clopidogrel following a STEMI.
Moving forward, the ideal duration and combination of
these treatments will continue to be studied and discussed
(8). Additionally, a better understanding of a given patient’s
underlying pathobiology and predisposition to recurrent
events may help in providing the most favorable antithrom-
botic strategy.
Rivaroxaban compared with placebo also resulted in a
dose-dependent increased rate of bleeding among STEMI
patients. Both doses of rivaroxaban led to significantly
higher rates of major, as well as medical attention, bleeding
events. However, there was no significant increase in the
risk of fatal bleeding with rivaroxaban compared with
placebo. When comparing the 2 active doses in STEMI
patients, the rates of bleeding were lower in the 2.5-mg
twice daily group compared with the 5-mg twice daily
group. Thus, the lower dose regimen resulted in a more
favorable safety profile and might explain, in part, the better
survival results with the very low dose of rivaroxaban.
Study limitations. Regarding limitations, this analysis
presents data from a subgroup of the trial, and therefore, the
Rivaroxaban 2.5 mg
Twice Daily vs. Placebo
Rivaroxaban 5 mg
Twice Daily vs. Placebo
Placebo
(n  2,599) HR (95% CI) p Value HR (95% CI) p Value
193 (10.6%) 0.81 (0.65–1.00) 0.047 0.81 (0.66–1.00) 0.051
172 (9.7%) 0.85 (0.68–1.06) 0.14 0.86 (0.69–1.07) 0.17
76 (4.2%) 0.60 (0.42–0.87) 0.006 0.92 (0.67–1.28) 0.64
67 (3.9%) 0.58 (0.39–0.86) 0.006 0.94 (0.66–1.33) 0.73
117 (6.7%) 0.84 (0.64–1.10) 0.21 0.72 (0.54–0.95) 0.019
103 (5.9%) 0.93 (0.70–1.23) 0.60 0.79 (0.59–1.05) 0.11
17 (0.8%) 1.43 (0.77–2.66) 0.26 1.47 (0.79–2.74) 0.22
16 (0.8%) 1.39 (0.73–2.66) 0.31 1.44 (0.76–2.74) 0.26
85 (4.7%) 0.63 (0.45–0.89) 0.008 0.99 (0.73–1.35) 0.97
73 (4.3%) 0.60 (0.41–0.87) 0.007 0.92 (0.66–1.28) 0.62
l infarction and stroke categories include fatal and nonfatal events. Stroke includes ischemic,
dified ITT.d
8)
)
)
)
)
)
)
)
)
)
)
ocardiapower to detect treatment differences is reduced, especially
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Rivaroxaban in STEMI May 7, 2013:1853–9among endpoints with low event rates and potentially
within the mITT analysis. Specifically, the mITT analysis
included fewer events than the ITT analysis, and the 95%
CIs were generally wider with the mITT approach, in some
cases crossing the line of unity. However, the ITT and
mITT analysis sets yielded directionally consistent results
throughout. Additionally, the potential of multiple testing
Figure 4 Incidence of the Primary Efficacy Endpoint and All-Ca
The primary efficacy endpoint consists of cardiovascular death, MI, or stroke. Data
BID  twice daily; other abbreviations as in Figure 1.
Safety EndpointsTable 3 Safety Endpoints
Safety Endpoints
Rivaroxaban
2.5 mg
(n  2,566)
5 mg
(n  2,552)
Combined
(n  5,180)
TIMI major bleed not
associated with CABG
32 (1.7%) 47 (2.7%) 79 (2.2%)
TIMI minor bleed 15 (0.8%) 25 (1.9%) 40 (1.3%)
TIMI medical attention
bleed
248 (12.6%) 316 (15.7%) 564 (14.1%)
Intracranial hemorrhage 7 (0.4%) 9 (0.8%) 16 (0.6%)
Fatal bleeding 1 (0.04%) 8 (0.4%) 9 (0.2%)Values are n (%). Event rates are reported as Kaplan-Meier estimates through 24 months. *The p value f
TIMI  Thrombolysis In Myocardial Infarction; other abbreviations as in Tables 1 and 2.can occur within subgroup analyses. Nonetheless, this index
event subgroup was pre-specified and provides data rele-
vant to this important group of patients. Information
about the use of rivaroxaban in the acute STEMI setting
and specific details about the peri-STEMI management
(e.g., use of glycoprotein IIb/IIIa inhibitors) were not
available. The trial was designed to exclude patients with
eath Across the Individual Doses
resented for each of the rivaroxaban doses compared with placebo.
Rivaroxaban 2.5 mg
Twice Daily vs. Placebo
Rivaroxaban 5 mg
Twice Daily vs. Placebo
acebo
2,607) HR (95% CI) p Value HR (95% CI) p Value
(0.6%) 3.63 (1.73–7.61) 0.001 5.47 (2.68–11.17) 0.001
(0.5%) 1.70 (0.74–3.88) 0.20 2.87 (1.34–6.15) 0.005
(7.8%) 1.75 (1.42–2.14) 0.001 2.30 (1.89–2.80) 0.001
(0.1%) 7.15 (0.88–58.15) 0.031* 9.62 (1.22–75.94) 0.008
(0.1%) 0.34 (0.04–3.28) 0.33 2.76 (0.73–10.41) 0.12use D
are pPl
(n 
9
9
147
1
3rom the Cox proportional hazard model is 0.066.
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May 7, 2013:1853–9 Rivaroxaban in STEMIan increased risk of bleeding and thus would not apply to
these patients.
Conclusions
Among patients stabilized after a STEMI, rivaroxaban
reduced cardiovascular events compared with placebo. This
Figure 5 Incidence of TIMI non-CABG Major Bleeding
Data are presented for each of the rivaroxaban doses as compared with pla-
cebo. CABG  coronary artery bypass graft; TIMI  Thrombolysis In Myocardial
Infarction; other abbreviations as Figures 1 and 4.
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Figure 6 Safety Endpoints
Kaplan-Meier event rates at 2 years are presented for each of the rivaroxaban
doses and placebo. ICH  intracranial hemorrhage; other abbreviations as in
Figures 4 and 5.reduction emerged within the first 30 days of the study.
Moreover, the benefit of rivaroxaban was evident despite the
use of antiplatelet therapies, as confirmed by analyses that
included patients continuing their background medications.
Within the STEMI group, the survival benefit with the
2.5-mg twice daily dose persisted and was not seen with the
higher dose of rivaroxaban. As a Xa inhibitor, rivaroxaban
was associated with higher rates of bleeding than placebo,
with the 2.5-mg twice daily dose of rivaroxaban exhibiting
a better safety profile than the 5-mg twice daily dose. Thus,
the addition of rivaroxaban 2.5-mg twice daily dose may
offer an effective strategy to reduce thrombotic events in
patients following a STEMI.
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